

# MELANIS - Survival in adult patients with BRAF V600 mutation-positive advanced melanoma: a non-interventional ambispective study of a cohort of patients treated with cobimetinib during the French early access program (TAU)

Head :Roche Medical data center

Last update : 11/26/2021 | Version : 1 | ID : 74085

General	
Identification	
Detailed name	Survival in adult patients with BRAF V600 mutation-positive advanced melanoma: a non-interventional ambispective study of a cohort of patients treated with cobimetinib during the French early access program (TAU)
Sign or acronym	MELANIS
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	ML29964
General Aspects	
Medical area	Cancer research Dermatology, venereology
Study in connection with Covid-19	No
Pathology (details)	Onco dermatology, BRAF V600 melanoma
Health determinants	Medicine
Keywords	cobimetinib
Scientific investigator(s) (Contact)	
Name of the director	Roche Medical data center
Address	4 cours de l'Ile Seguin - 92100 Boulogne-Billancourt
Email	data_sharing.france@roche.com
Organization	Roche SAS

## Collaborations

Participation in projects, networks and consortia	No
---	----

## Funding

Funding status	Private
----------------	---------

## Governance of the database

Sponsor(s) or organisation(s) responsible	Roche SAS
---	-----------

Organisation status	Private
---------------------	---------

Presence of scientific or steering committees	Yes
---	-----

## Additional contact

## Main features

### Type of database

Type of database	Study databases
------------------	-----------------

Study databases (details)	Cohort study
---------------------------	--------------

Database recruitment is carried out by an intermediary	A selection of health institutions and services
--	---

Database recruitment is made on the basis of:	Medication(s) taken
---	---------------------

Database recruitment is carried out as part of an interventional study	No
--	----

## Database objective

Main objective	<p>Primary Objective: To estimate the OS of patients treated with cobimetinib in combination with vemurafenib</p> <p>Secondary Objectives:</p> <ul style="list-style-type: none"><li>- To assess the PFS</li><li>- To identify prognostic factors of OS</li><li>- To identify prognostic factors of PFS</li><li>- To describe response to treatment (overall assessment of the physician)</li><li>- To describe time to treatment discontinuation.</li><li>- To characterize the targeted AE of cobimetinib in combination with vemurafenib under real-world</li></ul>
----------------	--

conditions of useTo describe the long term safety profile of cobimetinib in association with vemurafenib under real-world conditions of use  
Exploratory Objectives:

- To describe population of patients treated with cobimetinib in combination with vemurafenib
- To describe the use of cobimetinib in combination with vemurafenib

#### Inclusion criteria

Inclusion criteria:

- Patients at least 18 years-old
- Patients included in the TAU from 26 February 2015
- Patients with BRAF V600 mutation-positive unresectable or metastatic melanoma treated with cobimetinib in combination with Zelboraf® (vemurafenib)
- For alive patients: patients who have been informed verbally and in writing about this study who do not object to their data being electronically processed or subjected to data quality control and who have signed the consent form

OR

- For patients who died before the inclusion period: patients who did not expressed their opposition when they were alive.

Exclusion criteria:

- Alive patients unable to give informed consent
- Patients previously included in cobimetinib clinical trial.

#### Population type

##### Age

Adulthood (19 to 24 years)  
Adulthood (25 to 44 years)  
Adulthood (45 to 64 years)  
Elderly (65 to 79 years)  
Great age (80 years and more)

##### Population covered

Sick population

##### Pathology

C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue

##### Gender

Male  
Woman

##### Geography area

National

#### Data collection

##### Dates

Date of first collection (YYYY or MM/YYYY)	2016
Date of last collection (YYYY or MM/YYYY)	2018
Size of the database	
Size of the database (number of individuals)	< 500 individuals
Details of the number of individuals	198
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data
Clinical data (detail)	Medical registration
Details of collected clinical data	Type of data collected : informed consent, inclusion/exclusion criteria, date of the visit, demographic data, clinical data, medical history, disease history and prior melanoma therapies, treatment with cobimetinib, concomitant medications for melanoma (including vemurafenib), first disease progression, evaluation of lesions (as assessed by the physician), vital status, targeted adverse events (before inclusion), adverse events (after inclusion), early study termination.
Presence of a biobank	No
Health parameters studied	Health event/morbidity Health event/mortality Health care consumption and services
Procedures	
Data collection method	eCRF
Classifications used	CDISC like
Quality procedure(s) used	GCP/GVP
Participant monitoring	Yes
Monitoring procedures	Monitoring by contact with the referring doctor

Followed pathology	C00-C75 - Malignant neoplasms, stated or presumed to be primary, of specified sites, except of lymphoid, haematopoietic and related tissue
Links to administrative sources	No
Promotion and access	
Promotion	
Access	
Dedicated website	<a href="https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html">https://www.roche.fr/fr/innovation-recherche-medicale/data-sharing-portail-d-information-partage-des-donnees.html</a>
Presence of document that lists variables and coding procedures	Yes
Access to aggregated data	Access on specific project only
Access to individual data	Access on specific project only